Seeking Alpha

AstraZeneca licenses Merck cancer drug

  • AstraZeneca (AZN) has licensed Merck's (MRK) MK-1775 drug for certain types of ovarian cancer.
  • AstraZeneca will pay $50M up front, milestones and then royalties on any product sales.
  • MK-1775 is in Phase IIa trials in combination with standard-of-care therapies. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: